Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients
article
OA: closed
CC0
AI-generated summary
This survey of 118 hereditary angioedema patients over a long period assessed the benefits and risks associated with danazol treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BackgroundHereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Treatment with androgens prevents attacks for those with this condition.ObjectiveTo examine the benefits and risks of long-term treatment with danazol.MethodsData were generated retrospectively from 118 German and Danish patients who had HAE due to C1 inhibitor deficiency and were treated with danazol from 2 months to 30 years. The frequency and severity of acute attacks were registered before and during danazol treatment, and adverse effects to the treatment were noted. Data were collected by using standardized questionnaires.ResultsIn all, 111 of 118 patients responded to danazol. During treatment, 54 of the 118 patients (45.8%) became symptom free or had 1 attack or less per year. In the other patients, hereditary angioedema ran a mild course. The frequency of acute attacks during danazol treatment was reduced to 16.2%, and the attacks were considerably milder than before treatment. Laryngeal edema was reduced to 4.8%. Adverse effects (weight gain, virilization, menstrual irregularities, headache, depression, and/or liver adenomas) occurred in 93 of the 118 patients and led to discontinuation of danazol therapy in 30 patients.ConclusionsDanazol is highly beneficial in patients with frequent and severe attacks of HAE. Because the risk of adverse effects is high, close monitoring of patients is mandatory. However, many patients accept the adverse effects of prophylactic treatment to avoid the distressing and sometimes life-threatening attacks of this condition.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Acute pancreatitis associated with danazol treatment for endometriosis 1994
- Individual Replacement Therapy (IRT) with a Pasteurized C1-Inhibitor Concentrate Compared to Prophylaxis with Danazol in Patients with Hereditary Angioedema (HAE) - a Prospective Study. 2004
- Bile duct hamartoma occurring in association with long-term treatment with danazol. 1997
- BILE DUCT HAMARTOMA OCCURRING IN ASSOCIATION WITH LONG‐TERM TREATMENT WITH DANAZOL 1997
References (38)
- Acute pancreatitis associated with danazol treatment for endometriosis via openalex
- Bile duct hamartoma occurring in association with long-term treatment with danazol. via openalex
- BILE DUCT HAMARTOMA OCCURRING IN ASSOCIATION WITH LONG‐TERM TREATMENT WITH DANAZOL via openalex
- Individual Replacement Therapy (IRT) with a Pasteurized C1-Inhibitor Concentrate Compared to Prophylaxis with Danazol in Patients with Hereditary Angioedema (HAE) - a Prospective Study. via openalex
- W1971042333 via openalex
- W1982763532 via openalex
- W1987353096 via openalex
- W1988578052 via openalex
- W1993465482 via openalex
- W1999733114 via openalex
- W2000450248 via openalex
- W2004395480 via openalex
- W2010485658 via openalex
- W2022160378 via openalex
- W2036977780 via openalex
- W2041540648 via openalex
- W2046900174 via openalex
- W2051794823 via openalex
- W2071303623 via openalex
- W2071579747 via openalex
- doi:10.1007/bf02031976 via openalex
- W2074130634 via openalex
- W2078264642 via openalex
- W2088853327 via openalex
- W2102953371 via openalex
- W2125474642 via openalex
- W2136174251 via openalex
- W2164980913 via openalex
- W2165932126 via openalex
- W2170807355 via openalex
- W2397706268 via openalex
- W4246556938 via openalex
- W4252939281 via openalex
- W1522956225 via openalex
- W6655686031 via openalex
- W1559340507 via openalex
- W1586883593 via openalex
- W1966185086 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK